SupplementDrug
Palmidrol clinical trials
Also written Palmitoylethanolamide and Levagen™.
- studies test it
- 26
- open now
- 9
- in phase 3
- 1
- first study started
- 2012
Keep track of what changes. Save the palmidrol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
26 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 2
- 12
- Phase 3
- 1
- Phase 4
- 1
- No phase
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 18
RDC Clinical Pty Ltd (5) · University of Westminster (2) · Quantum Biopharma (2) · Academic and Community Cancer Research United (1) · Benha University (1) · Rodrigo Machado-Vieira, MD, PhD, MSc (1) · Brigham and Women's Hospital (1) · University of Maryland, Baltimore (1)
Often tested with
Tested in the same studies.
Curcumin (2) · Ultra-micronized Palmitoyl Ethylamine (PEA) FSD-201 (2) · Acetylcysteine (1) · Echinacea extract (1) · Dronabinol (1) · Lavender oil (1) · N-oleoylethanolamine (1)
Studies
Open first, then newest update. How each study uses palmidrol is read from its arms, and is right about nine times in ten.
Testing it · 26
- Palmitoylethanolamide in Ulcerative ColitisRecruitingNot applicableAin Shams UniversityNCT07609810Written as Palmitoylethanolamide (PEA)
- Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back PainRecruitingNot applicableBeni-Suef UniversityNCT07772141Written as Palmitoylethanolamide
- Intra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration.Not yet recruitingNot applicableUniversita di VeronaNCT07680101Written as micronized Palmitoylethanolamide (mPEA) 300mg + ultramicronized Palmitoylethanolamide (umPEA) 600mg
- Sleep and Stress StudyRecruitingPhase 2RDC Clinical Pty LtdNCT07315516Written as Palmitoylethanolamide (PEA)
- Training Health Recovery and Improvement Via Levagen+® EvaluationRecruitingNot applicableUniversity of WestminsterNCT07359534Written as Levagen+® Palmitoylethanolamide (PEA)
- Levagen+ Efficacy Study on Diabetic Peripheral NeuropathyRecruitingPhase 2RDC Clinical Pty LtdNCT07028528Written as Levagen+
- Palmitoylethanolamide for Chronic Inflammatory Pain ConditionsRecruitingPhase 2Navy Medical Center San DiegoNCT06273462Written as Palmitoylethanolamide 600mg twice a day
- PEA in Functional DyspepsiaRecruitingNot applicableUniversitaire Ziekenhuizen KU LeuvenNCT05877781Written as Palmitoylethanolamide
- PEA vs. Placebo for Major DepressionRecruitingPhase 2The Israeli Medical Center for Alzheimer'sNCT06063369Written as Palmitoylethanolamide
- Palmitoylethanolamide vs Ibuprofen for Pain After ESWLCompletedNot applicableBenha UniversityNCT07316660Written as Palmitoylethanolamide (PEA)
- Long-Term PEA Safety StudyActive, not recruitingPhase 2RDC Clinical Pty LtdNCT06717867Written as Palmitoylethanolamide (PEA)
- A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar DepressionCompletedPhase 2Rodrigo Machado-Vieira, MD, PhD, MScNCT06229977Written as Palmitoylethanolamide (PEA)
- Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)TerminatedPhase 2Quantum BiopharmaNCT05652907Written as FSD201
- Endocannabinoids, Stress, Craving And Pain Effects StudyCompletedEarly Phase 1Brigham and Women's HospitalNCT05480072Written as Palmitoylethanolamide
- PEA for the Relief of Chemotherapy-Induced Peripheral NeuropathyActive, not recruitingPhase 2Academic and Community Cancer Research UnitedNCT05246670Written as Palmidrol
- Effectiveness of PEA Compared to Placebo on Acute Menstrual PainCompletedPhase 4RDC Clinical Pty LtdNCT05810116Written as Levagen+
- Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee OsteoarthritisCompletedNot applicableUniversity of Maryland, BaltimoreNCT05406726Written as palmitoylethanolamide
- Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University StudentsCompletedNot applicableUniversity of WestminsterNCT06225440Written as Levagen+® Palmitoylethanolamide (PEA)
- A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.CompletedPhase 3RDC Clinical Pty LtdNCT05046522Written as Palmitoylethanolamide sold as Levagen +
- Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture FixationWithdrawnPhase 2University of California, IrvineNCT05317676Written as Palmitoylethanolamide
Codes
What other systems call palmidrol · ClinicalTrials.gg INT002354
- MeSH (NLM) C005958palmidrolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6R8T1UDM3VPALMIDROLConfirmed FDA, NLM, Wikidata
- RxNorm 2001986One source FDA
- Wikidata Q2159860palmidrolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66294PalmidrolOne source FDA
- DrugBank DB14043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C005958 | palmidrol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6R8T1UDM3V | PALMIDROL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2001986 | — | One source FDA |
| Wikidata | Q2159860 | palmidrol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66294 | Palmidrol | One source FDA |
| DrugBank | DB14043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.